Catalyst Financial Partners LLC Has $398,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Catalyst Financial Partners LLC raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 977 shares of the pharmaceutical company’s stock after buying an additional 36 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Vertex Pharmaceuticals were worth $398,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. National Pension Service raised its stake in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. National Pension Service now owns 450,621 shares of the pharmaceutical company’s stock valued at $183,353,000 after purchasing an additional 9,128 shares in the last quarter. Bogart Wealth LLC raised its stake in shares of Vertex Pharmaceuticals by 9.2% in the fourth quarter. Bogart Wealth LLC now owns 17,805 shares of the pharmaceutical company’s stock valued at $7,245,000 after purchasing an additional 1,501 shares in the last quarter. RMR Wealth Builders raised its stake in shares of Vertex Pharmaceuticals by 15.3% in the fourth quarter. RMR Wealth Builders now owns 2,965 shares of the pharmaceutical company’s stock valued at $1,206,000 after purchasing an additional 393 shares in the last quarter. Gryphon Financial Partners LLC raised its stake in shares of Vertex Pharmaceuticals by 26.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock valued at $805,000 after purchasing an additional 414 shares in the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $18,296,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 2.1 %

Vertex Pharmaceuticals stock traded up $8.58 during mid-day trading on Wednesday, reaching $418.82. The company’s stock had a trading volume of 1,651,186 shares, compared to its average volume of 1,234,831. The company has a market capitalization of $108.25 billion, a price-to-earnings ratio of 30.15, a price-to-earnings-growth ratio of 1.89 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40. The business’s 50 day simple moving average is $408.02 and its 200 day simple moving average is $400.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.67 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of recent research reports. Truist Financial upped their target price on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Sanford C. Bernstein lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. StockNews.com upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 3rd. Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research note on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $432.18.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,381 shares of company stock valued at $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.